Grafapex (treosulfan) / Medac, Medexus - LARVOL DELTA

Prognostic impact of mixed chimerism with undetectable measurable residual disease in pediatric and adolescent young adult patients undergoing allogeneic hematopoietic stem cell transplantation for hematological malignancies (ASH 2025) - "Conditioning regimens included TBI-based (n=4), busulfan-based (n=2), and treosulfan-based (n=2). Lineage-specific chimerism analysis offers superior prognostic value over global assessments. Standardized monitoring protocols are essential to guide post-HSCT management and avoid unnecessary and harmful interventions."

Clinical • Residual disease • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Oncology • Pediatrics • Pneumonia • Respiratory Diseases • Transplantation

efficacy and safety of treosulfan- vs. busulfan-based conditioning regimens in adult allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes and acute myeloid leukemia: A systematic review and meta-analysis. (ASH 2025) - "Treosulfan-based conditioning regimens offer favorable efficacy and safety compared to busulfan, with reduced NRM and improved donor chimerism without compromising engraftment or increasing GVHD or relapse risk. These findings support Treosulfan as a clinically effective and better-tolerated alternative, particularly for older or medically vulnerable transplant recipients."

Retrospective data • Review • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Transplantation

Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL) (ASH 2025) - "While Fludarabine plus Busulfan(FluBu) is a very popular RIC regimen, data from a randomized controlled trial have demonstratedsuperior overall survival (OS) with Treosulfan (FluTreo) instead of Busulfan as alkylating agent (3 year OS67 vs. 56%; Beelen et al., Am J Hematol, 2022). A scientific companion programincludes spatial assessment of the bone marrow microenvironment under therapy and monitoring ofchimerism via single nucleotide polymorphism using digital PCR. The study was submitted via CTIS on30.07.2025 and will start enrollment early in 2026."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Sarcoma • Solid Tumor • Transplantation

Treosulfan-based vs. busulfan-based conditioning for hematopoietic stem cell transplantation: A systematic review and meta-analysis. (ASH 2025) - "No substantial or significance differenceswere observed between regimens for toxicity (RR = 1.11, p = 0.72), TRM (RR = 0.84, p = 0.69), NRM (RR =0.93, p = 0.84), or relapse incidence (RR = 1.47, p = 0.11).ConclusionAlthough most outcomes between Treosulfan- and Busulfan-based regimens were statisticallycomparable, Treosulfan demonstrated non-inferiority in toxicity, TRM, NRM, and relapse incidence, alongwith consistently favorable results in OS, EFS, GVHD, and engraftment. These findings, reinforced bysensitivity analysis, emphasize the robustness of the results and highlight Treosulfan's potential as areliable conditioning agent for broader clinical application."

Retrospective data • Review • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation

Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial (ASH 2025) - "Using a classical 3+3 design, patientsreceived escalating doses of Venetoclax starting on day -11, one day before a 4-day treatment withFLAMSA (day -10 to -7, Fludarabine 30 mg/m2/day, Amsacrine 100 mg/m2/day and Cytarabine 2 g/m2/day,1 g/m2/day for patients older than 60 years)...Allogeneic peripheral blood stem cellswere infused on day 0 and GvHD prophylaxis consisted of tacrolimus, mycophenolate mofetil and a totaldose of 30 mg/kg ATG. A total of 9 patients (3 female) at a median age of 62 years (range 56 - 69) were included in thephase I part of the study (6 MDS, 2 CMML, 1 AML, all having active disease and unfavorable biology).Three patients received a total daily dose of 200 mg, 3 of 400 mg, 2 of 800 mg and 1 of 1600 mgVenetoclax in combination with FLAMSA... Smart conditioning using Venetoclax up to a daily dose of 800 mg in addition to FLAMSA-Treosulfan is safe. Hematopoietic reconstitution was not impaired and general toxicity of this sequentialconditioning..."

Clinical • P1/2 data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myelomonocytic Leukemia • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Myelodysplastic Syndrome • Neutropenia • CD34

Treosulfan – based conditioning in allogeneic hematopoietic stem-cell transplantation for lymphoid malignancies: Long term follows up. (ASH 2025) - "However, most of the data derives from HSCT inmyeloid malignancies and there is limited data on the outcome of HSCT with Treosulfan conditioning inlymphoid malignancies.We have used the combination of fludarabine and treosulfan as the preferred conditioning regimen forallogeneic HSCT in patients (pts) with lymphoid malignancies, considered eligible for low to intermediatetransplant conditioning intensity, since the year 2009...GVHD prophylaxis included cyclosporine andmethotrexate or mycophenolate ATG was added to unrelated donor HSCT...Treosulfan- based conditioning can allow promising long-term OS in pts with a variety of lymphoidmalignancies. Consistent with data form HSCT in myeloid malignancies, it is associated with potent anti-malignancy effect combined with relatively low NRM and GVHD rates. HSCT outcomes should beinterpreted in view of the novel therapeutic options that were introduced in recent years for thetreatment of various lymphatic malignancies."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Oncology • Richter's Syndrome • T Cell Non-Hodgkin Lymphoma • Transplantation

A single-centre comparison of thiotepa-treosulfan versus thiotepa-busulfan based conditioning regimens in adults with haematological malignancies undergoing allogeneic haematopoietic stem cell transplant. (ASH 2025) - "Treosulfan-based group: thiotepa-treosulfan-fludarabine (TTF) or thiotepa-etoposide-cyclophosphamide fludarabine-treosulfan (TEC-FT) regimens.Busulfan-based group: thiotepa-busulfan-fludarabine (TBF) or thiotepa-etoposide-cyclophosphamidebusulfan-fludarabine (TEC-BF) regimens. There were similar 1-year OS, CIR, GRFS rates and adverse events.Limitations of this retrospective analysis include small sample size predisposing to potential samplingbias. Randomized prospective studies are needed to assess the potential of double alkylator combinationof thiotepa and treosulfan in adults with haematological malignancies."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cardiovascular • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Liver Failure • Mucositis • Oncology • Portal Hypertension • Transplantation

Lentiviral vector transduced autologous CD34+ cells with FVIII transgene for gene therapy of Hemophilia A with history of inhibitors (ASH 2025) - "He was then started on immune toleranceinduction (ITI) with 25 IU/kg of extended half-life FVIII (Eloctate®) three times a week in December, 2022.For a trauma related oral bleeding in January, 2023, he was given one dose of emicizumab 3mg/kg withwhich his bleeding stopped within 24 hours...The conditioning protocol for the HSCT consisted ofmyeloablative doses of treosulfan along with fludarabine followed by infusion of the transduced CD34+gene therapy product cryo-preserved from November, 2022...This case demonstrates the first successful sustained expression of measurable FVIII activity in plasmaafter gene therapy for hemophilia A with history of inhibitors which had resolved after immune toleranceinduction. Gene therapy with LV transduced autologous CD34+ cells technology holds promise forhemophilia A patients with inhibitors and needs to be further explored."

Gene therapy • Viral vector • Bone Marrow Transplantation • Gene Therapies • Hematological Disorders • Hemophilia • Hemophilia A • Hypotension • Infectious Disease • Inflammation • Mood Disorders • Mucositis • Neutropenia • Rare Diseases • Respiratory Diseases • Septic Shock • Tuberculosis • CD34

Donor-derived CAR-T cells co-infused with the allogenic graft on the platform of T cell depletion or post-transplant cyclophosphamide in children with advanced B-cell neoplasms (ASH 2025) - "All patients had disease relapse after multiple lines of treatmentincluding previous HSCT(n=13), blinatumomab (n=22), inotuzumab (n=2), blinatumomab+inotuzumab(n=6) and CAR-T cell infusion(n=12)...The median proportion ofCD19-positive cells in the leukemic population was 100% (0–100%), while the median proportion of CD22-positive cells was 100% (36–100%).Fourteen (36%) pts received treosulfan-based myeloablative preparative regimen and TBI-based regimenwas used in 25 (64%) pts...Inthe PtCy group GVHD prophylaxis included abatacept, vedolizumab and CsA or baricitinib ResultsThere was no suspected conflict between the graft and CAR-T cells...We have documented CAR-T expansion and persistence. Prospective testing of theapproach is warranted."

CAR T-Cell Therapy • Clinical • Metastases • Post-transplantation • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Transplantation • CD22

Factors associated with the development of second primary malignancies after allogeneic stem cell hematopoietic transplantation. no association with In Vivo T-cell depletion (ASH 2025) - "Sex, a second Allo-HSCT, donor type, graft source,TBI, busulfan, melphalan, thiotepa, and any grade of cGVHD or moderate-severe cGVHD were notsignificantly associated with SPMs...Fludarabine (HR 1.9; 95% CI,0.9–4.4; p=0.1) and treosulfan (HR 1.8; 95% CI, 0.8–4.4; p=0.2) lost statistically significance. SPMs remain a significant late complication after Allo-HSCT... SPMs remain a significant late complication after Allo-HSCT. GVHD prophylaxis with ATG orPTCy was not associated with increased SPM risk. Age at transplant >50y was the only independent riskfactor identified."

Preclinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lung Cancer • Lymphoma • Myelodysplastic Syndrome • Oncology • Solid Tumor • Transplantation

Outcomes with a combination of treosulfan and fludarabine in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis (ASH 2025) - "The Treosulfan and Fludarabine conditioning regimen demonstrates favorable efficacy in AML/MDSpatients undergoing allo-HSCT, with high engraftment and survival rates and low NRM. Safety outcomesremain a concern and necessitate further trials with larger patient populations and standardized dosingregimens."

Retrospective data • Review • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome

Haplo-identical transplantation in patients with myelofibrosis, a phase 2 prospective multicentric study (ASH 2025) - P2 | "In this phase 2 trial (registered atclinicaltrial.com as NCT04728490), transplantation from an haplo-identical donor was proposed inpatients without an HLA matched donor using fludarabine 30mg/m2/day (D) for 5 days – treosulfan10g/m2/D for 3 days– thiotepa 5 mg/kg for one day– post-translant cyclophosphamide 50 mg/kg ion day+3 and day +5 (PTCY) -ciclosporine and mycophenolate mofetil plateform. One-year overall survival was 67.9% (95%CI: 52.6– 87.6). One-year non-relapse mortality (NRM) was 32.1% (95%CI: 15.8 – 49.7).In conclusion, the primary endpoint of one-year relapse and rejection -free survival was achieved.However, the NRM is the first cause of failure, mainly due to acute GVHD, MOF and infections justifyingfurther investigations to reduce early toxicity."

Clinical • P2 data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Fibrosis • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Influenza • Myelofibrosis • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Thrombocytopenia • Transplant Rejection • Transplantation • ASXL1 • CALR • TET2

Role of fludarabine exposure on post-transplant outcomes in high-risk β-thalassemia patients undergoing allogeneic HCT with thiotepa/ fludarabine/ treosulfan conditioning (ASH 2025) - "However, low exposure to Flu may be asurrogate indicator of poor outcomes. More robust patient-specific parameters (pre-transplant riskfactors), the role of concomitantly administered drugs such a Treo and other pharmacodynamicmeasures should be considered along with the PK of Flu to better explain and predict transplantoutcomes."

Clinical • Post-transplantation • Beta-Thalassemia • Genetic Disorders • Graft versus Host Disease • Transplantation

Hematopoietic stem cell transplantation in 746 children with osteopetrosis: A study of the inborn errors working party of the EBMT (ASH 2025) - "Conditioning regimens were Busulfan/Fludarabine (n=310; 43.5% of knownvalues), Busulfan/Cyclophosphamide (n=236; 33.1%), Treosulfan/Fludarabine/Thiotepa (n=132; 18.5%), orother (n=34; 4.8%). In UVA, earlier HSCT (<6 months) contributed to improved vision preservation(p<0.001).Conclusion This is the largest study to date describing HSCT outcomes in children affected by OP.Although challenges remain in terms of risk of GF, VOD and TRM, survival has significantly improved overthe last decade, especially when an HLA matched donor is unavailable. Due to the complexity of OPpatients, it is recommended that HSCT is performed in large and experienced centers."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cardiovascular • Chronic Graft versus Host Disease • CNS Disorders • Endocrine Disorders • Epilepsy • Graft versus Host Disease • Hematological Disorders • Hepatology • Hypertension • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Ophthalmology • Orthopedics • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Thrombocytopenia • Transplantation • TCIRG1

New Age HCT Conditioning Regimens: What Works and Why? (ASH 2025) - "Agents like treosulfan provide safer conditioning with a favorable toxicity profile for patients with older age or medical comorbidities...In this session, we will provide a brief overview of conditioning regimens and their various levels of intensity and will summarize modern conditioning approaches via a discussion of three nuanced contemporary case studies. We will: 1) re-examine current conditioning regimen intensity categorization schemes; 2) discuss novel conditioning regimens for active or residual disease, and 3) explore further options to optimize efficacy without increasing toxicity in older and medically infirm individuals."

Bone Marrow Transplantation • Pediatrics • Transplantation

New Age Hematopoietic Stem Cell Transplantation: Same Donors, New Prophylaxis, Novel Engineering (Adult and Pediatric Perspectives) (ASH 2025) - "He highlights the effectiveness of post-transplant cyclophosphamide (PTCy), abatacept, and vedolizumab in preventing both acute and chronic GVHD. Therapies including JAK inhibitors, sirolimus, alpha-1 antitrypsin, anti-thymocyte globulin (ATG), and obinutuzumab maintenance are also reviewed, offering tailored options based on donor type and patient risk profiles.Dr...Agents like treosulfan provide safer conditioning with a favorable toxicity profile for individuals who are older, pediatric patients, or those with medical comorbidities. Additionally, methodologies for precise and targeted radiation delivery with minimal off-target effects are emerging. These advancements necessitate reexamination and harmonization of conditioning intensity stratification schemes for a more personalized and selective approach."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Pediatrics • Transplantation • CD34

Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant (clinicaltrials.gov) - P=N/A | N=144 | Active, not recruiting | Sponsor: Rigshospitalet, Denmark | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Nov 2026 | Trial primary completion date: Jun 2025 ➔ Nov 2026

Biomarker • Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report. (PubMed, ESMO Open) - "This is the first published case suggesting a potential role for leukotriene receptor antagonists in CYSLTR2-mutant UM. These findings support further preclinical and clinical investigation of montelukast as a repurposed therapy in this challenging disease entity."

IO biomarker • Journal • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • CYSLTR2

New age HCT conditioning regimens: what works and why? (PubMed, Hematology Am Soc Hematol Educ Program) - "Agents like treosulfan provide safer conditioning with a favorable toxicity profile for patients with older age or medical comorbidities and can lower the incidence of long-term complications for younger patients...A promising development is radioimmunotherapy-based regimens that preferentially deplete hematopoietic cells and spare nonhematopoietic tissues. These advancements necessitate reexamination and harmonization of conditioning intensity stratification schemes for a more personalized and selective approach."

Journal • Review • Transplantation

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: medac GmbH | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Aug 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Renal Disease • Transplantation • HLA-DRB1

Prediction of Sinusoidal Obstructive Syndrome after Allogeneic Stem Cell Transplantation Using Liver Stiffness Measurement By Fibroscan (ASH 2023) - "5/7 AML pts received a median of 4 (2-5) lines of chemotherapy before HSCT; 2/4 sAML pts got azacytidine/ venetoclax and all 4 MF pts received Ruxolitinib before HSCT...In 6/11 pts with LSM ≥7.2 kPa, the conditioning was modified; Treosulfan was given instead of BU (n=3), non-DAC instead of DAC protocol (n=3), reduced intensity instead of MAC (n=4), methotrexate was omitted (n=2). One pt received Defibrotide prophylaxis... Pts with a high risk for VOD may have a high baseline LSM. In these pts, modifying the planned conditioning and GVHD prophylaxis regimens to less hepato-toxic ones may reduce the incidence of subsequent VOD. LSM elevation after HSCT should increase awareness of SOS, while pts with hyperbilirubinemia and low LSM usually suffered from other causes of liver toxicity."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Fibrosis • Gastroenterology • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Cirrhosis • Lymphoma • Myelodysplastic Syndrome • Myelofibrosis • Obesity • Oncology • Portal Hypertension • Transplantation

Treosulfan Plus Fludarabine (TTF10) As Preparative Regimen before Haploidentical Trasplant in Elderly Patients with Acute Myeloid Leukemia (ASH 2024) - "Post-transplant cyclophosphamide (PT-CY) has been confirmed to be effective and safe as graft-versus-host disase (GVHD) prophylaxis in the setting of haploidentical SCT (Haplo-SCT)...Treosulfan, a water soluble, bifunctional alkylating drug, showed strong myelotoxic, immunosuppressive, and antileukaemic properties with favourable acute toxicity profile when combined with fludarabine in patients with AML or MDS.We report here the outcome of elderly AML pts receiving aplo-HSC with a Reduced Intensity Conditioning regimen including treosulfan and fludarabine followed by PT-CY as GVHD prophylaxis.Methods : This is a multicentric, retrospective study involving 4 Italian Transplant Units including pts with AML aged ≥65 receiving before Haplo-SCT as preparative regimen intravenous treosulfan 10 g/m² for 3 days plus intravenous fludarabine 30 mg/m² IV for 5 days (TTF10 regimen) with PTCY, micophenolato mofetil and cyclosporine as prevention of GVHD.Results : Between..."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases

Individualized Treosulfan-based conditioning improves outcomes of allogeneic hematopoietic transplantation for myelodysplastic syndrome: A 25-Year retrospective, population-based analysis. (PubMed, Transplant Cell Ther) - No abstract available

Journal • Retrospective data • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • Transplantation

Haploidentical STEM-Cell Transplantation for Children with ACUTE Leukemia and NON-Malignant Disorders, Using ΑΒ + T Cell /CD19 + B-Cell Depletion, a Single Center Experience (ASH 2023) - "For patients with BMF, busulfan or treosulfan/fludarabine was administrated...Patients with SCID, either did not recieved conditioning or received fludarabine/thiotepa/melphalan or treosulfan/fludarabin conditioning... αβ+/CD19+ haploidentical Hematopoietic stem cell transplantation can offer long-term survival for children with acute leukemia and NMD. For children with AL, we observed a presumed protective role for higher content of γδ+ T cell in the graft which need to be evaluate prospectively in a larger cohort. There were no cases of severe GVHD and the rate of grade 1-2 GVHD was low."

Clinical • Acute Graft versus Host Disease • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Leukemia • Oncology • Primary Immunodeficiency • Rare Diseases • Transplantation

High Risk of GvHD in Children Transplanted for Refractory Cytopenia of Childhood: Importance of Sufficient Exposure to Anti-Thymocyte Globulin (ASH 2023) - "Conditioning for MDS-RCC consisted mainly of treosulfan-based or busulfan-based regimens (56%and 36%, respectively); SAA patients were mainly conditioned with fludarabine-cyclophosphamide (63%) or cyclophosphamide only (29%). (a) Graft-versus-host-disease free, event free survival after HCT for pediatric severe aplastic anemia (SAA; blue line) or myelodysplastic syndrome-refractory cytopenia of childhood (MDS-RCC; red line). (B) Incidence of grade 2-4 acute GvHD in aBMF patients with post-HCT exposure to ATG below (purple) or above the median (yellow)."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Myelodysplastic Syndrome • Oncology • Pediatrics • Renal Cell Carcinoma • Transplantation